Conyers Dill & Pearman advised Urovant Sciences Ltd. (“Urovant”) on its initial public offering of 10,000,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of US$140 million. Urovant has granted the underwriters a 30-day option to purchase up to 1,500,000 additional common shares at the initial public offering price, less the underwriting discounts and commissions.
Urovant is a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions.
Director Neil Henderson and Associate Robert Alexander of Conyers’ Bermuda office advised on the matter.
